Universe Pharmaceuticals INC
UPC
$5.94
-$1.15-16.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.52M | 4.52M | 4.35M | 4.35M | 4.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.52M | 4.52M | 4.35M | 4.35M | 4.58M |
| Cost of Revenue | 2.85M | 2.85M | 2.78M | 2.78M | 2.99M |
| Gross Profit | 1.67M | 1.67M | 1.57M | 1.57M | 1.58M |
| SG&A Expenses | 2.37M | 2.37M | 1.58M | 1.58M | 2.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.27M | 5.27M | 4.65M | 4.65M | 5.74M |
| Operating Income | -750.10K | -750.10K | -294.60K | -294.60K | -1.16M |
| Income Before Tax | -777.40K | -777.40K | -193.70K | -193.70K | -1.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -777.40K | -777.40K | -193.70K | -193.70K | -1.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -777.40K | -777.40K | -193.70K | -193.70K | -1.64M |
| EBIT | -750.10K | -750.10K | -294.60K | -294.60K | -1.16M |
| EBITDA | -634.50K | -634.50K | -170.70K | -170.70K | -1.03M |
| EPS Basic | -1.38 | -1.38 | -0.34 | -0.34 | -4.72 |
| Normalized Basic EPS | -0.86 | -0.86 | -0.21 | -0.21 | -2.95 |
| EPS Diluted | -1.38 | -1.38 | -0.34 | -0.34 | -4.72 |
| Normalized Diluted EPS | -0.86 | -0.86 | -0.21 | -0.21 | -2.95 |
| Average Basic Shares Outstanding | 563.30K | 563.30K | 563.90K | 563.90K | 347.80K |
| Average Diluted Shares Outstanding | 563.30K | 563.30K | 563.90K | 563.90K | 347.80K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |